



SYNBIO®

SACCO
system
Supporting food culture & life

TECHNICAL INFORMATION

IDENTIFICATION

16S rDNA gene sequence analysis
RAPD method

SAFETY

Included in EFSA QPS list
(EFSA Journal 2017)

Absence of investigated
antibiotic resistance genes
(EFSA Journal, 2018, 16(3):5206)

BSE/TSE free

GMO free


Colorant free and hypoallergenic
(list of allergens in compliance with
Reg. UE 1169/2011)

SHELF LIFE

18 months at temperature $\leq -18^{\circ}\text{C}$
12 months at temperature $5 \pm 3^{\circ}\text{C}$

STABILITY (Log_{10} CFU/g)

Stability studied both on the blend and
on the dosage form (sachet)



L. rhamnosus IMC 501®

STRAIN DEPOSIT NUMBER
DSM 16104


L. paracasei IMC 502®

STRAIN DEPOSIT NUMBER
DSM 16105

CHARACTERISTICS

- Bile and acid tolerance >95%
- Survival in the GI tract
- Adheres to epithelial intestinal cell line HT-29.

SYNBIO® strains, *L. rhamnosus* IMC 501® and *L. paracasei* IMC 502®, showed comparable or superior adhesion to human intestinal HT-29 cells, compared to other commercial strains, in vitro.



- antimicrobial activity against pathogens, especially vs *Candida albicans*

Bacterial strain	Inhibition of growth* of				
	<i>E. coli</i> (ATCC 11775)	<i>S. aureus</i> (ATCC 25923)	<i>C. albicans</i> (ATCC 10261)	<i>C. perfringens</i> (ATCC 13124)	<i>S. mutans</i> (ATCC 20523)
<i>L. rhamnosus</i> IMC 501®	+++	++	++++	+++	+
<i>L. paracasei</i> IMC 502®	+	+++	++++	+++	+

* Inhibition zone: + <2.0-1.5 cm; ++ <2.0-2.5 cm; +++ <2.5-3.0 cm; ++++ >2.5-3.0 cm;

Reference: Verdenelli et al., 2009.



SYNBIO[®] AND HOUSE DUST MITE ALLERGY

Allergies occur when the immune system overreacts to environmental factors that are harmless to most individuals. One of the most prevalent allergies is caused by house dust mites (HDM). Between 65-130 million people are estimated to suffer from HDM allergy worldwide. In recent decades, the incidence of allergies has increased in Western countries, which has been strongly linked to a relative lack of microbial stimulation of the immune system during infancy and excessive hygienic practices during early childhood in Western households. An innovative treatment consists of modulating the gut microbiome through probiotics, prebiotics and synbiotics to prevent allergic disease.

SYNBIO[®] can alleviate the allergy symptoms caused by house dust mites.



CLINICAL TRIAL Single arm

30
with HDM
allergy

Subjects

18-41
Years old

Age group

15x10⁹
CFU/day

1:1 *L. rhamnosus* IMC 501
L. paracasei IMC 502
Inulin 0,115g/day

6
months

Intervention
period

RESULTS

• Susceptibility

57% of subjects had reduced sensitivity to allergens after the 6 months treatment

• Allergenic symptomatology and gastrointestinal well-being statistically improved in the synbiotic treatment (P<0.05):

*statistically significant difference (P<0.05) due to the synbiotic treatment

IMPROVED

- conjunctivitis
- dry eye
- lacrimation
- burning eye
- intestinal regularity
- easiness of defecation
- increase in stool volume
- bloating
- allergic cold
- fatigue
- fever
- itchiness
- cough
- nasal obstruction
- rhinorrhoea
- sneezing

• **Health-related quality of life:** all 30 subjects had a global score of 79±4.2 for the Psychological General Well-being Index that corresponded to a "no distress" general well-being after synbiotic treatment.

• **Recovery of probiotic strains from fecal samples:** after 6 months of synbiotic supplementation, *L. rhamnosus* IMC 501[®] and *L. paracasei* IMC 502[®] were detected with a frequency of about 93% and 87% respectively, in a sampled subset of 15 subjects.



SYNBIO[®] AND GUT HEALTH

The composition of the intestinal microbiota is greatly related to the health of the host. Oral administration of probiotics is suggested to have a positive effect on people's general wellbeing, specifically, the composition of the intestinal microbiota and resistance against pathogen colonization.

SYNBIO[®] improves intestinal microbiota and prevents harmful bacteria.
Moreover, it exerts a positive effect, in terms of improved bowel habits, on healthy adults.

CLINICAL TRIAL

Double-blinded, randomized, placebo controlled

50
healthy
adults

- 25 PROBIOTIC
- 25 CONTROL

23-65
Years old

Age group

1x10⁹
CFU/day

1:1 Daily dose of
L. rhamnosus IMC 501[®]
L. paracasei IMC 502[®]

12
months

Intervention
period

RESULTS



- improves intestinal microbiota in the probiotic group



- improves bowel habits

Mean Log CFU/g \pm SD

	<i>Lactobacillus</i>		<i>Bifidobacterium</i>	
	Culture method	Real-time PCR quantification	Culture method	Real-time PCR quantification
Before consumption	8.5 \pm 0.1	9.4 \pm 0.3	8.2 \pm 0.1	8.5 \pm 0.7
After consumption	10.5 \pm 0.2	11.1 \pm 0.5	10.3 \pm 0.2	10.1 \pm 0.9
After wash-out	9.4 \pm 0.1	9.8 \pm 0.6	8.4 \pm 0.2	8.4 \pm 1.0



For each graph subjects scored their symptoms using a discrete graduated scale:
0=worse, 5=no change, 10=best.
(■) Control group, (■) Probiotic group.

* Significantly different from control group, according to chi-squared test (P<0.005).

Reference: Verdinelli et al., 2011[a].





SYNBIO® AND SPORT - Reduction of oxidative stress

It is well known that intense physical activity induces oxidative stress. Several studies have established that specific strains of probiotics prevent and correct oxidative stress. In vitro studies with both intact cells and intracellular cell-free extracts of *L. rhamnosus* IMC 501® and *L. paracasei* IMC 502® showed an antioxidative effect of these strains through the inhibition of lipid peroxidation.

SYNBIO® displays a strong antioxidant activity: athletes may benefit from the ability of these probiotics to increase antioxidant levels and neutralize the effects of reactive oxygen species.



CLINICAL STUDY

double-blinded, randomized,
placebo controlled

24

male
athletes

- 12 CONTROL
- 12 PROBIOTIC

26-38

Years old

Age group

1x10⁹

CFU/day

1:1 Daily dose of
L. rhamnosus IMC 501®
L. paracasei IMC 502®

4

weeks

Intervention
period

RESULTS

MICROBIAL ANALYSIS:

Lactobacillus count increased significantly in the probiotic group. The SYNBIO® strain was detected in all the subjects within the probiotic group.

CHANGES IN PLASMA REACTIVE OXYGEN METABOLITES

The control group's level of Reactive Oxygen Metabolites (ROMs) at the end of the training was significantly higher than that measured before physical activity ($P < 0.05$), while no significant changes in ROMs were observed in the probiotic group. After exercise ROMs levels were higher in the control group compared to the probiotic group $P > 0.05$.





SYNBIO® can neutralize ROMs

PLASMA BIOLOGICAL ANTIOXIDANT POTENTIAL

In the probiotic group, the Biological Antioxidant Potential (BAP) increased after supplementation, despite physical activity ($P < 0.05$). BAP levels were higher in the probiotic group compared to the control ($P < 0.01$)



SYNBIO® supplementation increases the plasma antioxidant levels





SYNBIO® AND SPORT - Effect on respiratory and gastrointestinal symptoms in athletes

There is a heightened incidence of upper respiratory tract (URT) and gastrointestinal (GI) illness, particularly diarrhea, during intense training and competitions that may have negative consequences for athletic performance. The increase of URT infections in athletes is a demonstrated consequence of exercise-induced changes in the immune system, which create an opportunity for pathogens to establish themselves. Maintaining a healthy GI tract microbiota may possibly prevent the occurrence of infections and reduce their duration.

SYNBIO® supplementation improves GI well-being and reduces cold symptoms.

CLINICAL STUDY

double-blinded, randomized,
placebo controlled

160
male
cyclists

- 80 CONTROL
- 80 PROBIOTIC

29-41
Years old

Age group

1x10⁹
CFU/day

1:1 Daily dose of
L. rhamnosus IMC 501®
L. paracasei IMC 502®

12
weeks

Intervention
period


RESULTS

- Analysis revealed a significant increase in the faecal *Lactobacillus* cell counts post-treatment, in the probiotic group compared to the control
- Treatment with SYNBIO® significantly improved GI wellbeing and reduced cold symptoms.

IMPROVED

- intestinal regularity
- stool volume
- stool consistency
- ease of defecation
- borborygmi
- bloating
- flatulence
- constipation
- diarrhea
- abdominal pain and intestinal cramps
- cold frequency
- tiredness

PGWBI Psychological General Well-being Index scores of probiotic group significantly differ from control group: 88.3 VS 80.5 (P<0.05)



Significantly different from pre-treatment, according to the Student's t-test (P≤0.05)

► SYNBIO® improved wellbeing in male athletes, making it the perfect probiotic blend for individuals who exercise regularly in order to avoid a decline in GI and respiratory health.

Reference: Verdenelli et al., 2011(b).





SYNBIO®

REFERENCES

Verdenelli et al., Probiotic proprieties of *Lactobacillus rhamnosus* and *Lactobacillus paracasei* isolated from human faeces. Eur J Nutr. 2009.

Cecchini et al., Effects of synbiotics on house dust mite allergic symptoms: a baseline-controlled open-label study. International Journal of Probiotics & Prebiotics. 2016.

Verdenelli et al., Influence of a combination of two potential probiotic strains, *Lactobacillus rhamnosus* IMC 501 and *Lactobacillus paracasei* IMC 502 on bowel habits of healthy adults. Applied Microbiology. 2011(a).

Silvi et al., Probiotic-enriched foods and dietary supplement containing SYNBIO® positively affects bowel habits in healthy adults: an assessment using standard statistical analysis and Support Vector Machines. Int J Food Sci Nutr. 2014.

Martarelli et al., Effect of probiotic intake on oxidant and antioxidant parameters in plasma of athletes during intense exercise training. Curr microbiol. 2011.

Verdenelli et al., Effect of the probiotic combination SYNBIO® on respiratory and gastrointestinal symptoms in athletes. Prebiotics & Probiotics directory. 2011(b).



Download on
Apple Store & Google Play

Sacco System is the new international biotech centre for innovation in nutraceutical and pharmaceutical products. Sacco System provides its customers with healthy, natural and functional products. We can offer a flexible service, develop formulation into adopted dosage forms, toll manufacturing (from laboratory to pilot production) and partnership for the development, production and the sale of single or mix probiotic strains of property or patented.

saccosystem.com